FDA backs Astellas/Seattle Genetics bladder cancer drug

The FDA has quickly okayed Astellas and Seattle Genetics’ advanced bladder cancer drug enfortumab vedotin, one of the stars of this year’s ASCO conference that was considered an almost dead

FDA sets January action date for Keytruda in early bladder c...

FDA starts quick review of Astellas/Seattle Genetics’ bladde...

Roche scores with Tecentriq combo in first-line bladder canc...

Seattle Genetics and Astellas file bladder cancer drug in US

Seattle Genetics and Astellas have filed their antibody-drug conjugate enfortumab vedotin with the US drug regulator for advanced bladder cancer, after failure of chemotherapy and immunothe